Please check your internet connection and try again.
# Clobazam (oral formulation)
## Overview
Clobazam is a benzodiazepine derivative with anticonvulsant properties used as adjunctive therapy for seizures associated with Lennox-Gastaut Syndrome (LGS). It acts as a positive allosteric modulator of GABA-A receptors, enhancing inhibitory neurotransmission.
## Primary Indications
Adjunctive therapy for seizures in patients with Lennox-Gastaut Syndrome (LGS).
## Adult Dosing
* **Starting dose:** 5 mg twice daily (BID).
* **Titration:** Increase dose by 5 mg every week based on clinical response and tolerability.
* **Maintenance dose:** Typically 10-20 mg BID.
* **Maximum dose:** 20 mg BID (40 mg daily).
## Pediatric Dosing
* **LGS, 2 years and older:**
* **Starting dose:** 5 mg BID.
* **Titration:** Increase dose by 5 mg every week based on clinical response and tolerability.
* **Maintenance dose:** Generally 0.5-1 mg/kg/day divided BID.
* **Maximum dose:** 20 mg BID (40 mg daily).
* **Pediatric patients below 2 years:** Safety and efficacy have not been established.
## Dose Adjustments
* **Hepatic Impairment:** Use with caution. No specific dose adjustments are established, but consider starting at the lowest dose and titrating slowly.
* **Renal Impairment:** Use with caution. No specific dose adjustments are established, but consider starting at the lowest dose and titrating slowly.
## Contraindications
* Hypersensitivity to clobazam or any component of the formulation.
## Adverse Effects
* **Common:** Somnolence, sedation, decreased appetite, aggression, irritability, constipation, vomiting, abnormal gait, fatigue, insomnia, pyrexia.
* **Serious:** Severe skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis), somnolence/sedation, withdrawal symptoms (seizures, rebound insomnia, anxiety, nausea), suicidal ideation/behavior, dependence.
## Key Drug Interactions
* **CNS Depressants (e.g., alcohol, opioids, other benzodiazepines):** Increased risk of sedation, respiratory depression, and coma.
* **CYP2C19 Inhibitors (e.g., fluconazole):** May increase clobazam concentrations.
* **CYP2C19 Inducers (e.g., rifampin):** May decrease clobazam concentrations.
* **Phenobarbital, Phenytoin, Primidone:** Clobazam can increase serum concentrations of these antiepileptic drugs.
## Monitoring
* Monitor for seizure frequency and type.
* Monitor for signs of somnolence, sedation, and behavioral changes.
* Monitor for signs of drug withdrawal upon discontinuation.
* Monitor for paradoxical reactions.
## Clinical Pearls
* Clobazam should be initiated at a low dose and gradually titrated upward to minimize adverse effects.
* Abrupt discontinuation can lead to withdrawal symptoms, including seizures. Dosage should be tapered gradually.
* Patients receiving clobazam may require adjustments to other antiepileptic medications due to potential pharmacodynamic and pharmacokinetic interactions.
* Behavioral changes, including aggression and suicidal ideation, have been reported. Patients and caregivers should be educated to report these changes promptly.
**Disclaimer:** This information is intended for healthcare professionals and is not a substitute for current prescribing information. Always consult the official prescribing information and relevant clinical guidelines for complete details before making any treatment decisions.
